APA (7th ed.) Citation

Scagliotti, G. V., Eschbach, C., & Manegold, C. (2012). Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: A phase-II study. Journal of thoracic oncology, 7(6), . https://doi.org/10.1097/JTO.0b013e3182519d79

Chicago Style (17th ed.) Citation

Scagliotti, Giorgio V., Corinna Eschbach, and Christian Manegold. "Tasisulam Sodium (LY573636 Sodium) as Third-line Treatment in Patients with Unresectable, Metastatic Non-small-cell Lung Cancer: A Phase-II Study." Journal of Thoracic Oncology 7, no. 6 (2012). https://doi.org/10.1097/JTO.0b013e3182519d79.

MLA (9th ed.) Citation

Scagliotti, Giorgio V., et al. "Tasisulam Sodium (LY573636 Sodium) as Third-line Treatment in Patients with Unresectable, Metastatic Non-small-cell Lung Cancer: A Phase-II Study." Journal of Thoracic Oncology, vol. 7, no. 6, 2012, https://doi.org/10.1097/JTO.0b013e3182519d79.